TickerFacts.

Allarity Therapeutics, Inc. (ALLR): Cash & Equivalents

Annual figures by period end, from SEC filings.

$14.69M
As of 2025-12-31
$16.98M
As of 2026-06-30
+93.4%
3-year compound annual growth
$19.53M2022-12-31: $2.03M2023-12-31: $166.0K2024-12-31: $19.53M2025-12-31: $14.69M$14.69M
2022-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$14.69M-24.8%2026-03-30, Balance as of period end
2024-12-31$19.53Mn/m2026-03-30, Balance as of period end
2023-12-31$166.0K-91.8%2025-03-31, Balance as of period end
2022-12-31$2.03Mn/a2024-03-08, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Allarity Therapeutics, Inc. (ALLR)2025-12-31$14.69M-24.8%
Vyome Holdings, Inc (HIND)2025-12-31$4.98Mn/m
Provectus Biopharmaceuticals, Inc. (PVCT)2025-12-31$251.3K-18.3%
Abvc Biopharma, Inc. (ABVC)2025-12-31$681.5K+174.4%
Can-Fite BioPharma Ltd. (CANF)2025-12-31$5.53M+14.6%
Medicinova Inc (MNOV)2025-12-31$30.81M-23.7%
Scienture Holdings, Inc. (SCNX)2025-12-31$6.66Mn/a
Regen BioPharma Inc (RGBP)2025-09-30$69.6Kn/m
Mereo BioPharma Group plc (MREO)2025-12-31$40.99M-41.3%

Compare ALLR, HIND, PVCT, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗